BIOCRYST PHARMACEUTICALS INC financial statements, including revenue, expenses, profit, and loss
The total revenue of BO1 for the last quarter is 85.97 M EUR, and it's 1.59% higher compared to the previous quarter. The net income of Q1 24 is -32.79 M EUR.